Cyclosporine A, alpha-interferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: A phase II study in advanced melanoma

Cancer Investigation

Volumn 23, Issue 1, 2005, Pages 3-8

  Feun, Lynn ^a   Marini, Angela ^a   Moffat, Frederick ^a   Savaraj, Niramol ^a   Hurley, Judith ^b   Mazumder, Amitabha ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Cyclosporine; Interferon; Interleukin; Melanoma

Indexed keywords

ALPHA INTERFERON; CARMUSTINE; CISPLATIN; CYCLOSPORIN A; DACARBAZINE; HISTAMINE; MELACINE; PACLITAXEL; RECOMBINANT INTERLEUKIN 2; TAMOXIFEN; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2;

ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; KAPLAN MEIER METHOD; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MELANOMA; NAUSEA; NEPHROTOXICITY; NEUROPATHY; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SEIZURE; SOFT TISSUE METASTASIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; ADULT; SKIN TUMOR; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CISPLATIN; CYCLOSPORINE; DACARBAZINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; INTERLEUKIN-2; MALE; MELANOMA; SKIN NEOPLASMS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 85047691573     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1081/CNV-46368     Document Type: Article

References (24)

1. Wittes, R.E.; Wittes, J.T.; Golbey, R.B. Combination chemotherapy in metastatic malignant melanoma. Cancer 1978, 41, 415-421.
2. Luikart, S.D.; Kennealey, G.T.; Kirkwood, J.M. Randomized phase II trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J. Clin. Oncol. 1984, 2, 164-168.
3. Del Prete, S.A.; Maurer, L.H.; O'Donnell, J.; Forcier, R.J.; LeMarbre, P. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat. Rep. 1984, 68, 1403-1405.
4. McClay, E.F.; Mastrangelo, M.J.; Bellet, R.E.; Berd, D. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat. Rep. 1987, 71, 465-469.
5. McClay, E.F.; Mastrangelo, M.J.; Sprandio, J.D.; Bellet, R.E.; Berd, D. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 1989, 63, 1292-1295.
6. Rusthoven, J.J.; Quirt, I.C.; Iscor, N.D.; McCulloch, P.B.; James, K.W.; Reinhard, R.C.; Lohmann, J.J.; Burdette-Radoux, S.; Bodurtha, A.J.; Silver, H.K.B.; Verma, S.; Armitage, G.R.; Zee, B.; Bennett, K. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J. Clin. Oncol. 1996, 14, 2083-2090.
7. O'Day, S.J.; Gammon, G.; Boasberg, P.D.; Martin, M.A.; Kristedja, T.S.; Guo, M.; Stern, S.; Edwards, S.; Fournier, P.; Weisburg, M.; Cannon, M.; Fawzy, N.W.; Johnson, T.D.; Essner, R.; Foshag, L.J.; Morton, D.L. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J. Clin. Oncol. 1999, 17, 2752.
8. Falkson, C.I.; Ibrahim, J.; Kirkwood, J.M.; Coates, A.S.; Atkins, M.B.; Blum, R.H. Phase III trial of dacarbazine versus dacarbazine with Interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 1998, 16, 1743.
9. Feun, L.G.; Savaraj, N.; Moffatt, F.; Robinson, D.; Liebmann, A.; Hurley, J.; Raub, W.A., Jr.; Richman, S.P. Phase II trial of recombinant alpha-interferon with BCNU, cisplatin, DTIC, and tamoxifen in advanced, malignant melanoma. Melanoma Res. 1995, 5, 273-276.
10. Legha, S.S.; Ring, S.; Eton. O.; Bedikian, A.; Buzaid, A.C.; Plager, C.; Papadapoulos, N. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastdine, dacarbazine, interferon alfa and interleukin-2 for patients with metastatic melanoma. J. Clin. Oncol. 1998, 16, 1752.
11. Keilholz, U.; Goey, S.H.; Punt, C.J.; Proebstle. T.M.; Salzmann, R.; Scheibenbogen, C.; Schadendorf, D.; Lienard, D.; Enk, A.; Dummer, R.; Hantich, B.; Geueke. A.-M.; Eggermont, A.M.M. Interferon alfa-2a and interleukin 2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J. Clin. Oncol. 1997, 15, 2579-2588.
12. Rosenberg, S.A.; Yang, J.C.; Schwartzentruber, D.J.; Hwu, P.; Marcincola, F.M.; Topalian, S.L.; Seipp, C.A.; Einhorn, J.H.; White, D.E.; Steinberg, S.M. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin 2 and interferon alfa-2a. J. Clin. Oncol. 1999, 17, 968.
13. Eton, O.; Legha, S.S.; Bedikian, A.Y.; Lee, J.J.; Buzaid, A.C.; Hodges, C.; Ring, S.E.; Papadopoulos, N.E.; Plager, C.; East, M.J.; Zhan, F.; Benjamin, R.S. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase II randomized trial. J. Clin. Oncol. 2002, 20, 2045-2052.
14. Hess, A.D.; Hormtz; Beschorner, W.E.; Santos, G.W. Development of graft versus host disease-like syndrome in cyclosporin-treated rats after syngeneic bone marrow transplantation. J. Exp. Med. 1985, 161, 718-730.
15. Perry, L.L.; Dorf, M.e.; Benacerraf, B.; Greene, M.I. Regulation of immune response to tumor antigen: interference with syngeneic tumor immunity by anti-IA alloantisera. Proc. Natl. Acad. Sci. 1979, 76, 920-924.
16. Charak, B.S.; Agah, R.; Mazumder, A. Synergism of interleukin-2 and cyclosporine A in induction of a graft versus tumor effect without graft versus host disease after syngeneic bone marrow transplantation. Blood 1992, 79, 179-184.
17. Kroczek, R.A.; Black, C.D.; Barbet, J.; Shevach, E.M. Mechanism of action of cyclosporin A in vivo: cyclosporin A fails to inhibit T lymphocyte activation in response to alloantigens. J. Immunol. 1987, 139, 3597-3603.
18. Thomson, A.w.; Moon, D.K.; Inoue, Y.; Geczy, C.L.; Nelson. D.S. Modification of delayed type hypersensitivity reactions to ovalbumin in cyclosporin A-treated guinea pigs. Immunology 1983, 48, 301-308.
19. Noble, R.L.; Steinmuller, D. Blocking of interleukin-2 production but not the tissue destruction induced by cytotoxic T cells by cyclosporine. Transplantation 1989, 47, 322-326.
20. Jones, R.J.; Vogelsang, S.B.; Hess, A.D.; Farmer, E.R.; Mann, R.B.; Cellar, R.B.; Piantadosi, S.; Santos, G.W. Induction of graft versus host disease after autologous bone marrow transplantation. Lancet 1989, 2, 754-756.
21. Rosenberg, S.; White, D. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. 1996, 19, 81-84.
22. Atkins, M.B.; Lee, S.; Flaherty, L.E.; Sosman, J.A.; Sondak, V.K.; Kirkwood, J.M. A prospective randomized phase III trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial. Proc. Am. Soc. Clin. Oncol. 2003, 22, 708.
23. Hu, H.-M.; Poehlein, C.H.; Urba, W.J.; Fox, B.A. Development of antitumor immune responses in reconstituted lymphopenic hosts. Can. Res. 2002, 62, 3914-3919.
24. Dudley, M.E.; Wunderlich, J.R.; Robbins, P.F.; Yang, J.C.; Hwu, P.; Schwartzentruber, D.J.; Toopalian. S.L.; Sherry, R.; Restifo, N.P.; Hubicki, A.M.; Robinson, M.R.; Raffeld, M.; Duray, P.; Seipp, C.A.; Rogers-Freezer, L.; Morton, K.E.; Mavroukakis, S.A.; White, D.E.; Rosenberg, S.A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298, 850-854.